Autolus Therapeutics Dirección
Dirección controles de criterios 4/4
El CEO de Autolus Therapeutics es Chris Itin , nombrado en Mar 2016, tiene una permanencia de 8.67 años. compensación anual total es $2.45M, compuesta por 22.5% salario y 77.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.4% de las acciones de la empresa, por valor de $2.99M. La antigüedad media del equipo directivo y de la junta directiva es de 3.1 años y 4.7 años, respectivamente.
Información clave
Chris Itin
Chief Executive Officer (CEO)
US$2.4m
Compensación total
| Porcentaje del salario del CEO | 22.5% |
| Permanencia del CEO | 8.7yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 3.1yrs |
| Promedio de permanencia en la Junta Directiva | 4.7yrs |
Actualizaciones recientes de la dirección
Recent updates
AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
Nov 21Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Sep 06Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?
Aug 15
Autolus Therapeutics: Major Inflection Point On The Horizon
Jul 31Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
May 14We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely
Nov 06Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
Jun 26We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth
Mar 09Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?
Dec 12Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy
Oct 12Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching
Aug 17Autolus Therapeutics Q2 2022 Earnings Preview
Aug 03Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
Apr 19We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully
Dec 15Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$270m |
| Jun 30 2024 | n/a | n/a | -US$234m |
| Mar 31 2024 | n/a | n/a | -US$221m |
| Dec 31 2023 | US$2m | US$551k | -US$208m |
| Sep 30 2023 | n/a | n/a | -US$158m |
| Jun 30 2023 | n/a | n/a | -US$155m |
| Mar 31 2023 | n/a | n/a | -US$152m |
| Dec 31 2022 | US$3m | US$502k | -US$149m |
| Sep 30 2022 | n/a | n/a | -US$164m |
| Jun 30 2022 | n/a | n/a | -US$155m |
| Mar 31 2022 | n/a | n/a | -US$146m |
| Dec 31 2021 | US$3m | US$543k | -US$142m |
| Sep 30 2021 | n/a | n/a | -US$143m |
| Jun 30 2021 | n/a | n/a | -US$147m |
| Mar 31 2021 | n/a | n/a | -US$145m |
| Dec 31 2020 | US$4m | US$522k | -US$142m |
| Sep 30 2020 | n/a | n/a | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$130m |
| Mar 31 2020 | n/a | n/a | -US$127m |
| Dec 31 2019 | US$5m | US$517k | -US$124m |
| Sep 30 2019 | n/a | n/a | -US$104m |
| Jun 30 2019 | n/a | n/a | -US$89m |
| Mar 31 2019 | n/a | n/a | -US$68m |
| Dec 31 2018 | n/a | n/a | -US$58m |
| Sep 30 2018 | US$2m | US$403k | -US$45m |
Compensación vs. Mercado: La compensación total ($USD2.45M) de Chris está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.20M).
Compensación vs. Ingresos: La compensación de Chris ha sido consistente con los resultados de la empresa en el último año.
CEO
Chris Itin (60 yo)
8.7yrs
Permanencia
US$2,449,092
Compensación
Dr. Christian Martin Itin, also known as Chris, Ph D., has been the Chief Executive Officer of Autolus Therapeutics Plc. (Former Name: Autolus Limited) since March 3, 2016.Dr. Itin has been Director of Au...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 8.7yrs | US$2.45m | 0.40% $ 3.0m | |
| Founder | 10.3yrs | sin datos | 0.26% $ 2.0m | |
| Senior VP & CFO | 1.3yrs | sin datos | sin datos | |
| Senior VP & COO | 8.1yrs | sin datos | 0.042% $ 314.2k | |
| Senior VP & Chief Technical Officer | 3.8yrs | sin datos | 0% $ 0 | |
| Senior VP & Chief Human Resources Officer | 3.1yrs | sin datos | 0% $ 0 | |
| Senior VP | no data | sin datos | 0.0035% $ 26.3k | |
| Director of Investor Relations | no data | sin datos | sin datos | |
| Senior VP of Legal Affairs & General Counsel and Secretary | 3.1yrs | sin datos | sin datos | |
| Senior VP & Chief Business Development Officer | less than a year | sin datos | 0.0031% $ 23.0k | |
| Senior Vice President of Project Management | 1.3yrs | sin datos | sin datos | |
| Senior Vice President of Medical Affairs | 1.8yrs | sin datos | sin datos |
3.1yrs
Permanencia media
58.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de AUTL se considera experimentado (3.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 10.1yrs | US$2.45m | 0.40% $ 3.0m | |
| Independent Non-Executive Director | 3yrs | US$224.14k | 0% $ 0 | |
| Chairman of the Board | less than a year | sin datos | sin datos | |
| Independent Non-Executive Director | 6.7yrs | US$209.89k | 0.0038% $ 28.0k | |
| Independent Non-Executive Director | 10.3yrs | US$207.98k | 0.051% $ 381.7k | |
| Independent Non-Executive Director | 10.2yrs | US$201.77k | 0% $ 0 | |
| Independent Non-Executive Director | 8.8yrs | US$207.98k | 0% $ 0 | |
| Independent Non-Executive Director | 6.4yrs | US$216.11k | 0% $ 0 | |
| Non-Executive Director | less than a year | sin datos | 0% $ 0 | |
| Non-Executive Director | 1.4yrs | US$171.92k | 0% $ 0 | |
| Non-Executive Director | less than a year | sin datos | sin datos | |
| Non-Executive Director | less than a year | US$16.22k | 0% $ 0 |
4.7yrs
Permanencia media
58.5yo
Promedio de edad
Junta con experiencia: La junta directiva de AUTL se considera experimentada (4.7 años de antigüedad promedio).